Canaccord analyst William Plovanic raised the firm’s price target on Boston Scientific to $64 from $62 and keeps a Buy rating on the shares. The firm attended its investor day where the company emphasized the importance of penetrating higher growth markets, noting that product launches will drive 8%-10% organic revenue CAGR from 2024-2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- CVS Health appoints Boston Scientific CEO Michael Mahoney to board
- Boston Scientific price target raised to $63 from $60 at Baird
- Boston Scientific price target raised to $60 from $56 at Mizuho
- Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
- Boston Scientific signs agreement to acquire Relievant Medsystems